Axonics, Inc.

Axonics, Inc. (Nasdaq: AXNX), relating to its proposed sale to Boston Scientific Corp. Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.

To receive more information regarding the investigation of Axonics, Inc. please fill out the form below.